Hemoglobin Hofu associated with beta 0-thalassemia. 1985

T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo

A mild anemia (hemoglobin 9 g/dl) was found in a patient from Seville (Spain) with marked morphological abnormalities in the peripheral blood smear. The red cell osmotic fragility showed a mild resistance curve with a mean cell fragility (MCF) of 0.375% NaCl (normal = 0.450). Chemical Chemical and thermal instability test and search for inclusion bodies gave positive results. Hemoglobin electrophoresis at pH 8.9 revealed absence of Hb A, a major component of fast mobility (94%), and increased Hb F and Hb A2 levels (1.5% and 4.6%, respectively). The fast fraction, isolated and purified by means of cellulose acetate electrophoresis, precipitated in acid acetone and treated with urea 8 M and mercaptoethanol, revealed an anomalous beta chain. Trypsin-digested globin peptides were separated by high-voltage electrophoresis at pH 6.4 and ascendant chromatography. With differential staining, an extra peptide was detected in an unusual site, more anodic than alpha Tp4 but in lower position. Peptide map of the fast beta chain, stained with ninhydrin, and also for Tyr, confirmed the position of the new peptide and the absence of the usual beta Tp13. The new peptide, separated by high-voltage electrophoresis at pH 3.5, revealed absence of Val and the presence of an additional Glu residue, which should appear only in position beta 126. The diagnosis of Hb Hofu (alpha 2 beta 2 126 Val----Glu; H4) was reached, thus interpreting its increase and the absence of Hb A, as an association with beta o-thalassemia, producing a mild hemolytic anemia. Evidence was obtained that Hb Hofu is a mild unstable hemoglobin variant.

UI MeSH Term Description Entries
D009996 Osmotic Fragility RED BLOOD CELL sensitivity to change in OSMOTIC PRESSURE. When exposed to a hypotonic concentration of sodium in a solution, red cells take in more water, swell until the capacity of the cell membrane is exceeded, and burst. Saline Fragility,Fragility, Osmotic,Fragility, Saline
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D005260 Female Females
D006455 Hemoglobins, Abnormal Hemoglobins characterized by structural alterations within the molecule. The alteration can be either absence, addition or substitution of one or more amino acids in the globin part of the molecule at selected positions in the polypeptide chains. Abnormal Hemoglobins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000743 Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES). Anemia, Hemolytic, Acquired,Anemia, Microangiopathic,Haemolytic Anaemia,Hemolytic Anemia,Hemolytic Anemia, Acquired,Microangiopathic Hemolytic Anemia,Acquired Hemolytic Anemia,Anaemia, Haemolytic,Anemia, Acquired Hemolytic,Anemia, Microangiopathic Hemolytic,Haemolytic Anaemias,Hemolytic Anemia, Microangiopathic,Microangiopathic Anemia,Microangiopathic Hemolytic Anemias
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias

Related Publications

T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
July 1989, Israel journal of medical sciences,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
January 1989, Lijecnicki vjesnik,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
October 2001, European journal of haematology,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
January 1979, Hemoglobin,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
June 1993, The Southeast Asian journal of tropical medicine and public health,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
April 1986, Blood,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
March 1990, American journal of clinical pathology,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
January 1988, The American journal of pediatric hematology/oncology,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
February 2008, Pediatric neurology,
T Arends, and G Garlín, and J M Guevara, and C Amesty, and O Pérez-Bández, and P A Lorkin, and H Lehmann, and O Castillo
November 2009, American journal of hematology,
Copied contents to your clipboard!